Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kaleido Biosciences, Inc. (KLDO)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
65 Hayden Avenue 2421
Lexington, MA, US
Lexington, MA, US
CEO
Mark A. Wingertzahn
Website
kaleido.com
IPO
2019-02-28
CIK 1751299 ISIN US4833471000
Description
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.8K
Beta
-1.17
Float Shares
42.45M
Free Float %
99.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | +0.00% | -50.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.48
+479,915.2%
DCF (Levered)
0.35
+349,398.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-15.62
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+13.2% ★ Q4'21: +102.5% (vs Q4'20)
-
EPS growth Biotechnology: +29.7%+11.5% Q4'21: +99.9% (vs Q4'20)
-
FCF margin FCF growth · Biotechnology: +16.2%-8,090.8% Q4'21: -3,576.4% (vs Q4'20)
-
EBIT margin Biotechnology: +0.0%-7,921.2% Q4'21: -3,975.0% (vs Q4'20)
-
ROIC Biotechnology: -16.1%— Q4'21: +1,267.3% (vs Q4'20)
-
Share dilution Biotechnology: -3.4%+25.1% Q4'21: +16.3% (vs Q4'20)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.25× Q4'21: -0.29× (vs Q4'20)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 13.75M (-100.0%)
|
975.0K
est: 12.20M (-92.0%)
|
1.10M
est: 1.67M (-33.9%)
|
1.00M
est.
|
30.00M
est.
|
97.98M
est.
|
150.47M
est.
|
| EBITDA |
-84.04M
est: 2.75M (-3,155.9%)
|
-77.00M
est: 2.44M (-3,255.7%)
|
-85.09M
est: 334.1K (-25,566.5%)
|
200.0K
est.
|
6.00M
est.
|
19.60M
est.
|
30.09M
est.
|
| EBIT |
-85.35M
est: 2.75M (-3,203.8%)
|
-78.82M
est: 2.44M (-3,330.4%)
|
-87.45M
est: 334.1K (-26,272.2%)
|
200.0K
est.
|
6.00M
est.
|
19.60M
est.
|
30.09M
est.
|
| Net Income |
-85.01M
est: -104.96M (+19.0%)
|
-81.62M
est: -96.28M (+15.2%)
|
-90.29M
est: -94.67M (+4.6%)
|
-48.56M
est.
|
-35.58M
est.
|
-8.79M
est.
|
25.95M
est.
|
| SGA |
22.43M
est: 127.84M (-82.5%)
|
23.88M
est: 113.42M (-78.9%)
|
20.97M
est: 15.53M (+35.0%)
|
9.30M
est.
|
278.92M
est.
|
910.93M
est.
|
1.40B
est.
|
| EPS |
-3.31
est: -2.51 (-32.0%)
|
-2.44
est: -2.30 (-6.1%)
|
-2.16
est: -2.26 (+4.5%)
|
-1.16
est.
|
-0.85
est.
|
-0.21
est.
|
0.62
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-79.86M
OE per share TTM
-1.92
Owner's Yield
-1,907,675.35%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,349.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 2.09M | 6.94% | — | — | 2.09M | — | IN | United States of America | 2020-02-07 | ↗ |
| 2 | FMR LLC | 2.09M | 6.94% | 784.9K | — | 2.09M | — | HC | Delaware | 2020-02-07 | ↗ |
| 3 | 1,833,832 | 1.83M | 12.00% | — | 1.83M | — | 1.83M | OO | — | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 0.86 | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
4.50
Bullish
Ratio by volume
3.00
Bullish
Buys
9
Sells
2
Shares acquired
1.31M
Shares disposed
4.1K
Cash buys
—
Cash sales
—
Net activity
+1,303,097
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-28 | van Hylckama Vlieg Johan | Officer | F-InKind | D | Restricted Stock Units | 2,087 | 1.49 | 3.1K | 4,620 | — | ↗ |
| 2022-02-28 | Korn Jerald | Officer | F-InKind | D | Restricted Stock Units | 2,046 | 1.49 | 3.0K | 4,517 | — | ↗ |
| 2022-01-14 | van Hylckama Vlieg Johan | Officer | A-Award | A | Restricted Stock Units | 350,000 | 0.00 | — | 350,000 | — | ↗ |
| 2022-01-14 | Menichella Daniel L | Director / Officer | A-Award | A | Restricted Stock Units | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-01-14 | Long Alison S | Officer | A-Award | A | Restricted Stock Units | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-01-14 | Korn Jerald | Officer | A-Award | A | Restricted Stock Units | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-01-14 | Duke William E. | Officer | A-Award | A | Restricted Stock Units | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2021-12-15 | Long Alison S | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 3.08 | 924.0K | 300,000 | — | ↗ |
| 2021-09-01 | van Hylckama Vlieg Johan | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 6.29 | 251.6K | 40,000 | — | ↗ |
| 2021-09-01 | Menichella Daniel L | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 6.29 | 691.9K | 110,000 | — | ↗ |
| 2021-09-01 | Korn Jerald | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 6.29 | 629.0K | 100,000 | — | ↗ |
| 2021-09-01 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 6.29 | 377.4K | 60,000 | — | ↗ |
| 2021-06-30 | von Maltzahn Geoffrey | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | Quinn Anthony G. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | Prener Anne | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | Mixer Jean K | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | Burnett Grady | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | Bassler Bonnie L | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-06-30 | BONNEY MICHAEL W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.44 | 111.6K | 15,000 | — | ↗ |
| 2021-05-05 | van Hylckama Vlieg Johan | Officer | — | D | Stock Option (Right to Buy) | 125,000 | 7.67 | 958.8K | 0 | — | ↗ |
| 2021-03-01 | Menichella Daniel L | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 9.81 | 882.9K | 90,000 | — | ↗ |
| 2021-03-01 | Korn Jerald | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 9.81 | 588.6K | 60,000 | — | ↗ |
| 2021-03-01 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 9.81 | 588.6K | 60,000 | — | ↗ |
| 2021-02-08 | Menichella Daniel L | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 11.50 | 230.0K | 20,000 | — | ↗ |
| 2021-02-08 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 71,667 | 11.50 | 824.2K | 2,982,639 | — | ↗ |
| 2020-10-15 | Menichella Daniel L | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 8.69 | 5.21M | 600,000 | — | ↗ |
| 2020-10-15 | Korn Jerald | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 8.69 | 391.1K | 45,000 | — | ↗ |
| 2020-10-15 | Knobil Katharine | Officer | A-Award | A | Stock Option (Right to Buy) | 67,500 | 8.69 | 586.6K | 67,500 | — | ↗ |
| 2020-10-15 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 8.69 | 434.5K | 50,000 | — | ↗ |
| 2020-10-13 | Menichella Daniel L | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | von Maltzahn Geoffrey | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | Quinn Anthony G. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | Prener Anne | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | Mixer Jean K | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | Burnett Grady | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | Bassler Bonnie L | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.43 | 111.5K | 15,000 | — | ↗ |
| 2020-06-30 | BONNEY MICHAEL W | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.42 | 111.3K | 15,000 | — | ↗ |
| 2020-06-04 | Nutritional Health LTP Fund General Partner LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 666,666 | — | ↗ |
| 2020-06-04 | MELAS KYRIAZI THEO | Director | P-Purchase | A | Common Stock | 33,333 | 7.50 | 250.0K | 33,333 | — | ↗ |
| 2020-06-04 | Flagship Ventures Fund IV General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 666,667 | 7.50 | 5.00M | 2,910,972 | — | ↗ |
| 2020-04-15 | Lawton Alison Frances | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 118,500 | 6.00 | 711.0K | 118,500 | — | ↗ |
| 2020-04-15 | Korn Jerald | Officer | A-Award | A | Stock Option (Right to Buy) | 45,000 | 6.00 | 270.0K | 45,000 | — | ↗ |
| 2020-04-15 | Knobil Katharine | Officer | A-Award | A | Stock Option (Right to Buy) | 67,500 | 6.00 | 405.0K | 67,500 | — | ↗ |
| 2020-04-15 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 6.00 | 300.0K | 50,000 | — | ↗ |
| 2020-04-01 | Prener Anne | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.21 | 156.3K | 30,000 | — | ↗ |
| 2020-02-28 | Lawton Alison Frances | Director / Officer | A-Award | A | Restricted Stock Units | 46,325 | 0.00 | — | 46,325 | — | ↗ |
| 2020-02-28 | Korn Jerald | Officer | A-Award | A | Restricted Stock Units | 6,563 | 0.00 | — | 6,563 | — | ↗ |
| 2020-02-28 | Knobil Katharine | Officer | A-Award | A | Restricted Stock Units | 15,843 | 0.00 | — | 15,843 | — | ↗ |
| 2019-11-29 | Duke William E. | Officer | A-Award | A | Stock Option (Right to Buy) | 270,000 | 8.71 | 2.35M | 270,000 | — | ↗ |
| 2019-11-22 | Duke William E. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-15 | Lawton Alison Frances | Director / Officer | A-Award | D | Stock Option (Right to Buy) | 150,000 | 6.56 | 984.0K | 150,000 | — | ↗ |
| 2019-11-15 | Korn Jerald | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 6.56 | 492.0K | 75,000 | — | ↗ |
| 2019-11-15 | Knobil Katharine | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 6.56 | 820.0K | 125,000 | — | ↗ |
| 2019-10-11 | Scalzo Richard William | Officer | — | D | Stock Option (Right to Buy) | 37,500 | 10.28 | 385.5K | 0 | — | ↗ |
| 2019-09-30 | Mixer Jean K | Director | A-Award | A | Stock Option (Right to Buy) | 97,626 | 7.53 | 735.1K | 97,626 | — | ↗ |
| 2019-07-31 | MELAS KYRIAZI THEO | Director | A-Award | A | Stock Option (Right to Buy) | 93,531 | 7.67 | 717.4K | 93,531 | — | ↗ |
| 2019-07-31 | Korn Jerald | Officer | A-Award | A | Stock Option (Right to Buy) | 180,000 | 7.67 | 1.38M | 180,000 | — | ↗ |
| 2019-07-22 | Korn Jerald | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-11 | MELAS KYRIAZI THEO | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-04 | von Maltzahn Geoffrey | Director | C-Conversion | A | Common Stock | 342,466 | 0.00 | 342.47 | 342,466 | — | ↗ |
| 2019-03-04 | Quinn Anthony G. | Director | C-Conversion | A | Common Stock | 12,853 | 0.00 | 12.85 | 31,603 | — | ↗ |
| 2019-03-04 | Lawton Alison Frances | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 15.00 | 2.25M | 150,000 | — | ↗ |
| 2019-03-04 | Flagship Ventures Fund V General Partner LLC | Director / 10% Owner | C-Conversion | D | Series B Preferred Stock | 2,570,694 | 0.00 | — | 0 | — | ↗ |
| 2019-03-04 | Flagship Ventures Fund IV General Partner LLC | Director / 10% Owner | C-Conversion | A | Common Stock | 665,908 | 0.00 | 665.91 | 665,908 | — | ↗ |
| 2019-03-04 | Brumm Joshua T | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 15.00 | 1.20M | 80,000 | — | ↗ |
| 2019-03-04 | BONNEY MICHAEL W | Director / Officer | C-Conversion | D | Series B Preferred Stock | 450,000 | 0.00 | — | 0 | — | ↗ |
| 2019-02-28 | BONNEY MICHAEL W | Director / Officer | P-Purchase | A | Common Stock | 68,965 | 13.95 | 962.1K | 1,005,968 | — | ↗ |
| 2019-02-27 | von Maltzahn Geoffrey | Director | — | D | Series A Preferred Stock | 342,466 | 0.00 | — | 0 | — | ↗ |
| 2019-02-27 | SCULLEY JOHN | Director | — | D | Stock Option (Right to Buy) | 50,000 | 15.20 | 760.0K | 0 | — | ↗ |
| 2019-02-27 | Quinn Anthony G. | Director | — | D | Stock Option (Right to Buy) | 31,250 | 0.30 | 9.4K | 0 | — | ↗ |
| 2019-02-27 | McIntyre Jonathan | Director | — | D | Stock Option (Right to Buy) | 5,000 | 2.18 | 10.9K | 0 | — | ↗ |
| 2019-02-27 | Lawton Alison Frances | Director / Officer | — | D | Stock Option (Right to Buy) | 162,500 | 2.22 | 360.8K | 0 | — | ↗ |
| 2019-02-27 | Knobil Katharine | Officer | — | D | Stock Option (Right to Buy) | 461,000 | 17.40 | 8.02M | 0 | — | ↗ |
| 2019-02-27 | Flagship Ventures Fund V General Partner LLC | Director / 10% Owner | — | I | Series A Preferred Stock | 4,637,555 | 0.00 | — | 0 | — | ↗ |
| 2019-02-27 | Flagship Ventures Fund IV General Partner LLC | Director / 10% Owner | — | I | Series A-1 Preferred Stock | 281,203 | 0.00 | — | 0 | — | ↗ |
| 2019-02-27 | Burnett Grady | Director | — | D | Stock Option (Right to Buy) | 50,000 | 11.78 | 589.0K | 0 | — | ↗ |
| 2019-02-27 | Brumm Joshua T | Officer | — | D | Stock Option (Right to Buy) | 124,089 | 10.28 | 1.28M | 0 | — | ↗ |
| 2019-02-27 | Bassler Bonnie L | Director | — | D | Stock Option (Right to Buy) | 50,000 | 17.40 | 870.0K | 0 | — | ↗ |
| 2019-02-27 | BONNEY MICHAEL W | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 937,003 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-11.5K
Shares Outstanding
42.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2020 | Daniel Menichella President and Chief Executive Officer (principal executive officer) | 118.7K | — | — | 3.78M | 49.0K | 1.7K | 3.95M | 95.71% | ↗ |
| 2 | 2020 | Katharine Knobil, M.D. Former CMO Head of RD | 450.0K | 75.7K | — | 805.8K | 157.6K | 12.5K | 1.50M | 53.66% | ↗ |
| 3 | 2020 | William Duke, Jr. Chief Financial Officer (principal financial officer) | 420.0K | 100.0K | — | 527.1K | 142.8K | 10.1K | 1.20M | 43.92% | ↗ |
| 4 | 2020 | Alison Lawton Former President and Chief Executive Officer (former principal executive officer) | 515.0K | — | — | 351.7K | 257.5K | 11.3K | 1.14M | 30.98% | ↗ |
| 5 | 2019 | Alison Lawton Former President and Chief Executive Officer (former principal executive officer) | 500.0K | 250.0K | — | 2.10M | 276.6K | 11.2K | 3.14M | 66.94% | ↗ |
| 6 | 2019 | Alison Lawton President and Chief Executive Officer (principal executive officer) | 500.0K | — | — | 2.10M | 276.6K | 11.2K | 2.89M | 72.73% | ↗ |
| 7 | 2019 | William Duke, Jr. Chief Financial Officer (principal financial officer) | 44.7K | — | — | 1.68M | — | 277.00 | 1.72M | 97.39% | ↗ |
| 8 | 2019 | Jerald Korn | 170.0K | 50.0K | — | 1.21M | 70.5K | 4.2K | 1.51M | 80.42% | ↗ |
| 9 | 2019 | Katharine Knobil, M.D. Former CMO Head of RD | 450.0K | 200.0K | — | 583.7K | 170.3K | 47.8K | 1.45M | 40.21% | ↗ |
| 10 | 2019 | Katharine Knobil, M.D. Chief Medical Officer and Head of Research Development | 450.0K | — | — | 583.7K | 170.3K | 47.8K | 1.25M | 46.63% | ↗ |
| 11 | 2019 | Joshua Brumm Chief Operating Officer and Chief Financial Officer (former principal financial officer) | 349.9K | — | — | 747.2K | — | 764.00 | 1.10M | 68.06% | ↗ |
| 12 | 2019 | Daniel Menichella President and Chief Executive Officer (principal executive officer) | — | — | — | — | — | — | — | — | ↗ |
| 13 | 2018 | Alison Lawton President and Chief Executive Officer (principal executive officer) | 437.5K | — | — | 5.95M | 250.0K | 9.5K | 6.64M | 89.51% | ↗ |
| 14 | 2018 | Katharine Knobil, M.D. Chief Medical Officer and Head of Research Development | 37.5K | — | — | 3.90M | — | 200.4K | 4.14M | 94.25% | ↗ |
| 15 | 2018 | Joshua Brumm Chief Operating Officer and Chief Financial Officer (former principal financial officer) | 296.9K | — | — | 2.11M | 126.1K | 320.6K | 2.85M | 73.92% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark A. Wingertzahn | Senior Vice President of R&D and Head of Development | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KLDO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
